Cortexyme Inc. logo

Cortexyme Inc.

Cortexyme is a private biopharma company, developing therapeutics to alter the course of Alzheimers and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration.

Cortexyme was founded based on the seminal discovery by Dr. Stephen Dominy of pathogenic bacteria in the brain of Alzheimers patients. Infection of mice with the same bacteria results in brain infiltration, neurodegeneration and other pathology of Alzheimers. Because the bacteria is persistent and resistant to broad spectrum antibiotics, Cortexyme is now developing small molecules to stop disease progression. Dr. Steve, studied contribution of proteins from the gut that pass through the blood-brain barrier and may affect the neural health of AIDS patients.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cortexyme.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
329 Oyster Point Blvd. #300, CA 094080
South San Francisco
United States
Email
Contact Number
+1 650 491 9638

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cortexyme-inc.” connections=”true” suffix=””]

COR388 is a first-in-class bacterial protease inhibitor that targets a pathogen identified in brain tissue and cerebral spinal fluid of patients with Alzheimers disease (AD)

In Jan 2016, Cortexyme raised $15 million in Series A financing led by Pfizer Inc., Takeda Pharmaceutical Company Ltd., through its venture arm, and Dolby Family Ventures.

In Oct 2014, Cortexyme received $ 500,000 angel funding from Dolby Family Ventures, including a 350,000$ investment award from the Thiel Foundations Breakout Labs for Alzheimers disease and other disorders of aging.

In May 2018, Cortexyme raised $76Mn in the series B round funding which included Sequoia Capital, Vulcan Capital, Alphabets Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital along with previous investors. It plans to move to phase 2 to prove the drugs efficacy with the help of the funds.